<DOC>
	<DOC>NCT02860780</DOC>
	<brief_summary>The main purpose of this study is to evaluate the safety of the study drug prexasertib in combination with ralimetinib in participants with advanced or metastatic cancer.</brief_summary>
	<brief_title>A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<criteria>Advanced or metastatic cancer. Able to swallow tablets. For Part B, you will need to have colon cancer or nonsmall cell lung (NSCLC) cancer with KRAS and/or BRAF mutations. Discontinued all previous treatments for cancer and recovered from the acute effects from the therapy. Active infection (fungal, viral, or bacterial). Active cancer in your brain or spinal cord. Acute or chronic leukemia. Serious heart condition. Disease that requires immunosuppressant therapy. Diagnosis of inflammatory bowel disease. Major small bowel resection that interferes with your body's ability to absorb the oral medicine. Participated in other clinical trials investigating prexasertib or ralimetinib. Pregnant or breastfeeding. Other preexisting conditions or medical history which your doctor will explain to you.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>